Monday, 31 October 2011

SAFC's Verona, WI, HPAPI facility has received SafeBridge certification

Contract Pharma

CMC Biologics has signed a three-year deal to provide process development support and manufacture for several clinical-stage antibodies for Daiichi Sankyo

Pharmaceutical Business Review

Fujifilm to manufacture ContraFect biologic

Fujifilm Diosynth Biotechnologies will use its pAVEway advanced protein expression technology at its Billingham, UK, facility to support the process development and cGMP manufacture of CF-301, ContraFect’s Staphylococcal-specific bacteriophage lysine.
Manufacturing Chemist

Prosonix has appointed a scientific board


Lonza to manufacture GenMab's HuMax-TF

Lonza will provide process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF in its Slough, UK facility. The antibody, which is expressed using Lonza’s GS Gene Expression System, will be conjugated at Lonza's plant in Visp, CH to a cytotoxic drug to form the antibody drug conjugate.

Panreac has launched Panreac Pharma, to providing GMP compliant excipients and pharmacopoeia grade raw materials

Manufacturing Chemist

Abbott plans to keep its contract manufacturing operations after it spins off its research-based pharma business

Outsourcing Pharma

Monday, 24 October 2011

Almac to increase manufacturing capacity

Almac is expanding manufacturing capacity to over 30m3 at its Craigavon, UK, headquarters. The company said the facility will include reactor vessels with state of the art clean room product isolation and drying equipment to allow HPAPI manufacture up to 600kg batch size. Almac anticipates that the facility will be built, commissioned and validated within the next two years.

Layoffs at Corden

Corden Pharma Colorado, the former Roche Colorado facility recently acquired by ICIG, is to lay off 60 of its 260 workers.
Boulder County Business Report

Lonza is considering building a new research centre in Singapore

Today online

Thursday, 20 October 2011

Lonza will begin trading on the Main Board of the Singapore stock exchange on 21 October

Business Times

Almac to expand pharmaceutical development capabilities

Almac will invest £4.5m in the first phase of expanding pharmaceutical development capabilities at its headquarters in Craiavon, Northern Ireland. The new laboratory scale facility, which is due for completion in mid-2012, will provide non-GMP formulation facility for the development and scale-up of solid oral dose drug products using a range of technologies. The second stage of the expansion will add dedicated analytical laboratories before the end of 2012.
Genetic Engineering and Biotechnology News

Lonza has completed its acquisition of Arch Chemicals


Carbogen Amcis and Polymun Scientific to team on HPAPI technologies

Carbogen Amcis will collaborate with Polymun Scientific to offer additional services for the development, manufacturing and formulation of HPAPIs. Carbogen Amcis will gain access to Polymun's innovative liposome technology for the formulation of APIs and Polymun will have access to Carbogen Amcis' expertise in the development and manufacture of highly potent APIs.
Carbogen Amcis

Wednesday, 19 October 2011

Hovione collaborates with Bend Research

Hovione and Bend Research will collaborate to offer their clients access to each other's capabilities. Bend Research will offer its clients access to Hovione’s commercial-scale pharmaceutical manufacturing facilities and Hovione clients will have access to Bend Research’s oral drug-delivery, formulation, and engineering expertise.
Bend Research

Monday, 17 October 2011

Lonza has successfully completed its tender offer for Arch Chemicals


Angel to establish jv

Angel Biotechnology is to establish a joint venture with Materia Medica Holding (MMH). The jv, which will be 51% owned by MMH and 49% owned by Angel, will commission new product programmes and manage their production in a dedicated GMP unit operated by Angel, on behalf of MMH. To manufacture products for MMH, Angel plans to increase the size of the GMP facility at Cramlington.
Proactive Investors

Profits fall at Aesica

Aesica's pre-tax profit in 2010 fell from £9.7m to £3.4m as sales fell slightly from £84.6m to £83.5m. The company said the closure of its Ponders End facility in London generated exceptional costs of £6.8m, including £3.1m primarily relating to redundancy payments.
Insider Media, Yorkshire

Aesica has entered a long-term strategic partnership with Mitovie Pharma to provide clinical trial and commercial batch supply and formulation development services


Saltigo to add HPAPI manufacturing capabilities

Saltigo is adding the capabilities to produce potent and highly potent APIs at its Redmond, WA, facility. Andreas Stolle, head of Saltigo's pharma business line, said the kilogram scale facility, aimed at supplying materials for phase I and II, will be available early in 2012. Additionally, Saltigo's Leverkusen site has been accredited by the Japanese Pharmaceuticals and Medical Devices Agency.

Wednesday, 5 October 2011

Aesica will manufacture codeine for Noramco


Carbogen Amcis completes inspection

Carbogen Amcis has successfully completed a US FDA pre-approval inspection for a new high potency drug. for a US multinational. Dishman's managing director JR Vyas said: "Post this approval, we expect business of around $10m per annum from our existing customers."
Money Control

Aesica gets new investor plans expansion

Silverfleet Capital has replaced LDC as the majority investor in Aesica. Silverfleet's investment will enable Aesica to continue its rapid expansion into new markets and achieve its vision of becoming the number one supplier of APIs and formulated products to the global pharmaceutical industry.
Contract Pharma

Cambridge Major's Weert, Netherlands, facility has been approved by Dutch authorities

Outsourcing Pharma

The FDA has informed AMRI that the corrective actions underway at its Burlington, MA, facility, should address its investigator's observations


Lonza will provide clinical and long-term commercial production of Mesoblast’s allogeneic adult stem cell products


Novasep will manufacture eicosapentaenoic acid for Photonz Corporation


CMC Biologics unveiled a $10m addition to its Bothell, WA, manufacturing plant

Everett Daily Herald